· Published by Health Canada · Official notice
This is duplicated text of a letter from GlaxoSmithKline Inc. Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
January 27, 2014
Subject: ARZERRA™ (ofatumumab) – Recommendations to screen, monitor and to manage hepatitis B virus reactivation
GSK, in consultation with Health Canada has informed health care professionals of important safety updates regarding the use of ARZERRA™.
ARZERRA™ is a medication that is administered into the veins to treat chronic lymphocytic leukemia (CLL), a type of blood cancer.
The prescribing information for ARZERRATM has been revised to include new recommendations for the screening, follow-up and management of patients with Hepatitis B reactivation.
GSK has sent a letter to healthcare professionals informing them of this important safety information. This information may be obtained on the Canadian website of GlaxoSmithKline Inc. or on the Healthy Canadians Web site.
Managing marketed health product-related side effects depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing side effects are generally presumed to underestimate the risks associated with health product treatments. Any case of serious hepatitis B recurrence or other serious or unexpected side effects in patients receiving ARZERRA™ should be reported to GlaxoSmithKline or Health Canada.
GlaxoSmithKline Inc.
7333 Mississauga Road
Mississauga, Ontario
L5N 6L4
Tel: 1-800-387-7374
You can report any suspected side effect associated with the use of health products to Health Canada by:
For other health product inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate
E-mail: mhpd_dpsc.public@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738
If you have any questions about this new information, please contact GlaxoSmithKline Medical Information Department at 1-800-387-7374.
original signed by
Vito S. Racanelli, MD
Dir Medical Affairs,
GlaxoSmithKline Inc.
™ARZERRA is used under license by GlaxoSmithKline Inc.